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Background: Remifentanil has been shown to be effective at treating potentially adverse hemodynamic responses 
to tracheal intubation even at low doses (< 1 μg/kg/min), which needs to be evaluated in patients with diverse 
cardiovascular conditions. 
Methods: A low-dose regimen of remifentanil (continuous infusion of 0.1 μg/kg/min, preceded by 0.5 μg/kg bolus) 
was given before induction with bolus propofol and rocuronium, and heart rate as well as systolic, diastolic, and 
mean arterial pressures were measured at 1 min intervals from before induction to 5 min after tracheal intubation in 
normotensive patients, untreated hypertensive patients, and patients with known hypertension. 
Results: The low-dose regimen of remifentanil resulted in parallel hemodynamic responses in all three groups, and 
was effective at limiting hemodynamic responses to tracheal intubation without excessive cardiovascular depression. 
Hemodynamic responses in our study showed a similar pattern to that reported in previous investigations, except for 
elevations in heart rate and arterial pressures over the baseline values immediately after intubation.
Conclusions: We suggest that the low-dose regimen of remifentanil in our study could be routinely used to modify 
hemodynamic responses to tracheal intubation in patients with diverse hemodynamic characteristics. However, the 
development of supplementary regimens is still needed to control the brief, but exaggerated responses to tracheal 
intubation, especially in untreated hypertensive patients. (Korean J Anesthesiol 2012; 62: 135-141)
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Introduction
Tracheal intubation can cause augmented sympathetic 
responses, resulting in tachycardia and/or hypertension, 
which are potentially deleterious to susceptible patients [1]. 
Patients with hypertension, whether treated or not, are prone to 
much greater swings of arterial pressure during induction and 
intubation, and are at greater risk of adverse events, including 
myocardial ischemia [2]. Various agents were shown to be 
effective at treating adverse hemodynamic responses during 
induction and tracheal intubation, such as anesthetics [3], 
analgesics [4,5], vasodilators [6], and sympathetic blocking 
agents [7]. Remifentanil is a recently developed opioid agent 
with potent analgesic effects characterized by rapid onset and 
offset, and is seemingly ideal for noxious but brief stimulation 
of tracheal intubation [8-10]. Hypertensive patients may not 
only have an exaggerated cardiovascular response to a noxious 
stimulus such as tracheal intubation, but also are at greater 
risk for developing hypotension after induction with potent 
anesthetics [2]. Therefore, a minimal but effective dosage of 
remifentanil needs to be determined. Low-dose remifentanil, 
being less than the manufacturer-recommended induction dose 
(1 μg/kg IV bolus followed by continuous infusion of 0.5-1 μg/
kg/min), was previously demonstrated to be equally effective 
at treating hemodynamic responses to tracheal intubation, 
compared with higher doses of remifentanil, and alfentanil in 
normotensive and hypertensive patients, respectively [11,12]. 
It has not yet been clarified, however, whether low-dose 
remifentanil has an equal effect on hemodynamic responses to 
tracheal intubation between normotensive and hypertensive 
patients, especially in Koreans, who were previously shown to 
have reduced sensitivity to remifentanil, likely resulting from 
ethnic differences [13,14]. 
The aim of this study was to evaluate the effects of low-dose 
remifentanil on hemodynamic responses to tracheal intubation 
in patients with untreated and treated hypertension, as well as 
in normotensive patients.
Materials and Methods
After obtaining approval from institutional review board of 
our hospital, and informed consent from all patients to use the 
hemodynamic data collected, 100 adult patients with American 
Society of Anesthesiologists physical status I-II, who were 
scheduled for elective spine surgery were recruited for this 
anonymous study. Patients with no history of antihypertensive 
medication and with a baseline hemodynamic of systolic 
arterial pressure (SAP) < 140 mmHg and diastolic arterial 
pressure (DAP) < 90 mmHg were assigned to the normotensive 
group (Group N), while those with a baseline hemodynamic 
of SAP > 140 mmHg or DAP > 90 mmHg were assigned 
to the untreated hypertensive group (Group UH). The 
baseline hemodynamic was an averaged value of duplicate 
hemodynamic measurements performed before induction 
of anesthesia. Patients with a history of antihypertensive 
medication(s) for > 6 months were assigned to the known 
hypertension group (Group KH). Any patient with anticipated 
difficulty with airway maintenance and/or intubation, 
concurrent diagnosis of congestive heart failure, renal 
failure, insulin-dependent diabetes mellitus or symptomatic 
arrhythmia, was excluded. 
Patients in Group KH were allowed to take their morning 
dose of antihypertensive medication(s) with sips of water 
on the day of surgery. Before leaving the ward, patients were 
provided with 0.05 mg/kg of midazolam intramuscularly as 
premedication. When patients arrived in the operating theater, 
glycopyrrolate 0.2 mg was given intravenously after confirming 
the patency of peripheral intravenous (IV) access. Standard 
monitoring included ECG, SpO2, non-invasive blood pressure, 
and end-tidal CO2 (ETCO2).
Remifentanil infusion of 0.1 μg/kg/min was initiated 
before induction of anesthesia, and maintained throughout 
the operation. Infusion of remifentanil was preceded by a 
bolus dose of remifentanil 0.5 μg/kg via a peripheral IV line. 
Anesthesia was induced with IV propofol 1 mg/kg over 30 sec, 
with an additional 10 mg administered every 10 sec until loss 
of verbal response. IV Lidocaine 30 mg was added to prevent 
injection pain with propofol. After loss of consciousness, 
rocuronium 0.6 mg/kg was given for neuromuscular relaxation 
while manual ventilation with 100% O2 (≥ 3 L/min) via a mask 
was maintained. Tracheal intubation was performed 3 min after 
induction of anesthesia with direct laryngoscopy for thoracic or 
lumbar surgery, or with a lightwand for cervical surgery. Then, 
mechanical ventilation was adjusted to have an ETCO2 of 35-40 
mmHg, and 1.5 vol% sevoflurane with 60% O2 in air (2-3 L/min) 
was used to maintain anesthesia. Hemodynamic measurements 
including heart rate (HR) and systolic, diastolic, and mean 
arterial pressures (SAP, DAP, and MAP) were performed at 1 
min intervals from before induction of anesthesia (baseline) to 
5 min after tracheal intubation. 
If SAP and/or HR increased by > 30% of baseline for > 60 sec 
(hypertension and/or tachycardia), the following treatments 
were performed as rescue therapy: an additional bolus dose of 
IV remifentanil 0.5 μg/kgwas given initially, and if hypertension 
and/or tachycardia persisted thereafter, sevoflurane 1.5 vol% 
was added. If SAP decreased by > 30% of baseline for > 60 sec 
(hypotension), IV ephedrine was given in 2 mg increments 
per min until SAP improved within 30% of baseline. If HR was 
reduced by > 30% of baseline for > 60 sec (bradycardia), IV 
atropine 0.5 mg was given.
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Based on previous investigations, power analysis suggested 
that > 30 patients per group would enable detection of a > 15 
mmHg difference in MAP between groups with a chance of 
80% (α = 0.05, β = 0.2) [11,12]. Data are presented as mean ± SD, 
median (interquartile range) or number of patients. Statistical 
analyses were performed using SPSS 15.0 for Windows (SPSS 
Inc, Chicago, IL, USA). Categorical data were examined 
using a chi-square test to compare groups. Continuous vari-
ables, such as demographic data, intubation-related data, 
and drug dosage, were tested with one-way ANOVA or a 
Kruskal-Wallis test, according to the normality test. Statistical 
analyses of hemodynamic data were performed as follows: 
one-way ANOVA was used for cross-sectional comparison 
between groups, and repeated measures ANOVA was used 
for longitudinal analysis with time and group as within- and 
between-subjects factors, respectively. For post hoc multiple 
comparisons, the Bonferroni method was used. A P value < 0.05 
was considered to be statistically significant.
Results 
Patient characteristics, intubation-related data and drug 
dosage are summarized in Table 1. More male patients were 
recruited to Group UH (P < 0.01, compared to Group KH). 
Patients in Group KH were older than those in Groups N and 
UH (P < 0.001 and P < 0.05, respectively). The proportion of 
lightwand to laryngoscopy use, and the weight-standardized 
dose of propofol, as well as elapsed time and number of 
attempts for intubation, were similar between the three groups. 
No patients presented with an ST change or dysrhythmia during 
induction or tracheal intubation. 
The antihypertensive medications used in Group KH are 
listed in Table 2. Angiotensin receptor blockers were the most 
frequently used agents, followed by calcium channel blockers. 
More than half of the patients were taking at least two different 
agents simultaneously (12 patients took two different drugs, 
and five patients took three different drugs). 
Numerical data of hemodynamic parameters over nine time 
points are presented in Table 3. The baseline HR was similar 
in all three groups. Baseline arterial pressures, however, were 
higher in Groups UH and KH than in Group N (P < 0.001, except 
for DAP in Group KH, P = 0.002). Moreover, the baseline DAP 
and MAP in Group UH were greater than in Group KH (P = 0.001, 
and P = 0.009, respectively).
After induction of anesthesia, HR and arterial pressures 
significantly decreased below the baseline values in all three 
groups (P < 0.001). With tracheal intubation, HR significantly 
increased over the baseline values in all three groups (P < 0.001). 
Within 5 min after tracheal intubation, HR gradually decreased 
to the baseline levels in Groups UH and KH. In Group N, 
however, HR remained higher than baseline value until 5 min 
after tracheal intubation (P = 0.008). Immediately after tracheal 
intubation, arterial pressures increased over the baseline 
values in all three groups. However, only DAP and MAP in 
Groups N and UH were significantly greater than baseline 
for 1 min after intubation (P < 0.001 and P = 0.003 for DAP, 
and P = 0.001 and P = 0.031 for MAP, respectively). Thereafter, 
arterial pressures decreased below the baseline values in all 
three groups (P < 0.01). Theses serial changes in HR and MAP 
are depicted in Fig. 1 as SAP and DAP changed in parallel to 
MAP over time. Changes in HR were not influenced by group 
discrimination. However, MAP changes over time in Group UH 
Table 1. Characteristics and Intubation-related Data
Group N
(n = 35)
Group UH
(n = 33)
Group KH
(n = 32)
Sex (M/F)
Age
BMI (kg/m2)
Intubation method
  (laryngoscopy/lightwand)
Elapsed time for
  intubation (min)
Intubation attempts 
  of ≥ 2 times
Dose of propofol (mg/kg)
15/20
 52.1 ± 12.6
24.1 ± 2.5
23/12
1.4 ± 0.9
 1
1.1 (1.0, 1.2)
22/11*
 57.5 ± 14.4
24.4 ± 3
22/11
1.4 ± 0.9
2
1.1 (1.0, 1.4)
11/21
65.8 ± 8†,‡
24.7 ± 3.9
23/9
1.9 ± 1.5
4
1.1 (1.0, 1.3)
Values are mean ± SD, median (interquartile range) or numbers, 
as appropriate. Group N: normotensive, Group UH: untreated 
hypertensive, Group KH: known hypertension. *P < 0.01, compared 
to Group KH, †P < 0.001, compared to Group N, ‡P < 0.05, compared 
to Group UH.
Table 2. Antihypertensive Medications Used in Patients with Known 
Hypertension (Group KH)
Antihypertensive medication Number of patients
ACEI + ARB + CCB
ACEI + CCB
ACEI + CCB + Diuretics
ARB
ARB + CCB
ARB + CCB + Diuretics
ARB +  Diuretics
ARB + β-blocker
ARB + β-blocker + CCB
CCB
CCB + Diuretics
α-blocker + CCB
β-blocker
β-blocker + CCB
β-blocker + CCB + Diuretics
β-blocker + Diuretics
1
1
1
8
4
1
2
1
1
5
1
1
2
1
1
1
Values are numbers. ACEI: angiotensin-converting enzyme inhibitor, 
ARB: angiotensin receptor blocker, CCB: Ca2+-channel blocker, 
α-blocker: α-adrenergic receptor blocker, β-blocker: β-adrenergic 
receptor blocker.
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were significantly different from those in Group N (P < 0.001).
Compared among groups, HR and arterial pressures in 
Groups UH and KH remained higher than those in Group N 
immediately after induction: in Group UH, HR and SAP for 1 
min (P = 0.023 and P < 0.001, respectively), and DAP and MAP 
for 2 min (P = 0.004); in Group KH, SAP and MAP for 1 min (P 
< 0.001, and P = 0.008, respectively). Thereafter, HR and arterial 
pressures all became comparable among groups immediately 
before intubation. After tracheal intubation, HR increased over 
the baseline values, but was comparable among groups. Arterial 
pressures in Group UH were greater than in Group N (P = 0.015, 
P = 0.023, and P = 0.008 for SAP, DAP, and MAP, respectively). 
Moreover, MAP in Group UH was higher than in Group KH (P = 
0.035). These increases in arterial pressures were observed for 1 
min after tracheal intubation and then disappeared, which was 
comparable among groups by 5 min after tracheal intubation, 
except that MAP in Group UH was significantly higher than in 
Group N at 4 min after intubation. 
Rescue therapy was given in 13 patients (two in Group N, 
eight in Group UH, and three in Group KH) without significant 
differences among groups. Most of the rescue therapy was to 
treat hypertension after intubation (one in Group N, seven in 
Group UH, and two in Group KH): only one patient in Group 
N presented with hypotension requiring ephedrine admini-
stration.
Discussion
In this study, we demonstrated that a low-dose regimen 
of remifentanil, consisting of a 0.5 μg/kg bolus followed by 
Table 3. Hemodynamic Data During Induction of Anesthesia and Tracheal Intubation Showing Comparisons Among Groups
Group N Group UH Group KH
HR (beats/min)
SAP (mmHg)
DAP (mmHg)
MAP (mmHg)
Baseline
After induction of anesthesia
After tracheal intubation
Baseline
After induction of anesthesia
After tracheal intubation
Baseline
After induction of anesthesia
After tracheal intubation
Baseline
After induction of anesthesia
After tracheal intubation
1 min
2 min
3 min
1 min
2 min
3 min
4 min
5 min
1 min
2 min
3 min
1 min
2 min
3 min
4 min
5 min
1 min
2 min
3 min
1 min
2 min
3 min
4 min
5 min
1 min
2 min
3 min
1 min
2 min
3 min
4 min
5 min
75.6 ± 13.1
72.6 ± 10.9
 71 ± 10.6
71.3 ± 17.6
98.7 ± 19.8
91.8 ± 18.9
 87 ± 16.4
82.5 ± 21
82.4 ± 15.6
123.4 ± 11.4
  116 ± 15.9
106.7 ± 15.7
 99.2 ± 22.5
133.1 ± 28.7
124.7 ± 26.7
111.5 ± 31.5
109.3 ± 18.2
106.3 ± 15.9
71.2 ± 8.3
65.5 ± 9.7
60 ± 8
58.9 ± 16
  84 ± 18.6
 76.9 ± 19.3
 67.7 ± 19.5
65.3 ± 12
63.3 ± 11
87.6 ± 8.8
82 ± 11.6
75 ± 10.3
72.5 ± 16.8
101.3 ± 20.3
92.4 ± 21.2
86.1 ± 18
80.1 ± 14.1
78.6 ± 11
82.8 ± 14.1
81.4 ± 14.4*
77.4 ± 12.7
73.9 ± 20.2
102.1 ± 23.7
93.4 ± 26.7
87.9 ± 17.8
85.7 ± 18.2
82.6 ± 16.3
154.6 ± 12.6†
137.7 ± 18.6†
 119 ± 19.1
106.2 ± 27.5
  156 ± 32.6*
142.5 ± 38
127.4 ± 23.8
122.4 ± 26.6
114.6 ± 22.7
85.9 ± 7.7†,‡
77.1 ± 11.8†
 69 ± 10.1§
64 ± 15.2
 97.6 ± 22.1*
85.3 ± 23.4
75.3 ± 16.6
72.6 ± 18.3
67.2 ± 12.3
 109.4 ± 10.7†,‡
97.8 ± 14†
86.6 ± 13.4§
77.8 ± 19.2
 119.2 ± 24.3§,∥
105.5 ± 27.9
94.5 ± 17.3
 90.6 ± 19.6*
83.8 ± 13.7
77.8 ± 12.6
77.3 ± 14.3
71.5 ± 18.2
74.2 ± 13.3
94.1 ± 18.2
88.7 ± 15.7
85.2 ± 13.5
82.6 ± 12.7
79.2 ± 13
150.9 ± 19†
134.4 ± 22†
113.8 ± 27
 109 ± 21
 143.4 ± 36.7
  143 ± 33.9
 128.8 ± 26.9*
118.7 ± 26.8
111.8 ± 21.9
78.4 ± 9§
 71.5 ± 11.3
65.6 ± 15
 63.3 ± 9.8
85.3 ± 21
 79.5 ± 16.1
73.5 ± 19
 67.9 ± 13.5
 65.7 ± 13.9
100.9 ± 13.7†
 92.1 ± 14.9§
80.1 ± 19.1
78.7 ± 14
103.8 ± 27.1
 98.6 ± 20.4
 91.6 ± 20.6
 84.7 ± 17.7
 81.7 ± 17.6
Values are mean ± SD. HR: heart rate, SAP: systolic arterial pressure, DAP:diastolic arterial pressure, MAP: mean arterial pressure. Group N: 
normotensive, Group UH: untreated hypertensive, Group KH: known hypertension. *P < 0.05, compared to Group N, †P < 0.001, compared to 
Group N, ‡P < 0.01, compared to Group KH, §P < 0.01, compared to Group N, ∥P < 0.05, compared to Group KH.
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continuous infusion of 0.1 μg/kg/min, given before induction 
of anesthesia with bolus propofol, resulted in similar 
hemodynamic responses to induction and tracheal intubation 
in patients with diverse cardiovascular conditions. Although the 
untreated hypertensive patients were shown to have statistically 
different hemodynamic responses from those in normotensive 
patients with relatively larger amplitude of pressure swing, this 
brief but exaggerated response clinically means nothing but 
requirement for additional rescue therapy for those patients. 
Furthermore, the low-dose regimen of remifentanil was also 
shown to be effective at stabilizing hemodynamics before 
intubation, and at limiting pressor responses to tracheal 
intubation without excessive cardiovascular depression. 
Remifentanil is considered to present the ideal pharmaco-
logical profile to treat potentially adverse hemodynamic res-
ponses to the noxious but brief stimulus of tracheal intubation. 
Earlier investigations with a remifentanil bolus with or without 
continuous infusion demonstrated that remifentanil effecti-
vely mitigated or even abolished those responses [15-17]. 
However, much higher doses of remifentanil were used than 
in our study and these higher doses of remifentanil were 
frequently (up to 50%) associated with bradycardia and/or 
hypotension, especially if no pretreatment with glycopyrrolate 
was performed [15-17]. Hall et al. [11] demonstrated that a 
0.5 μg/kg bolus of remifentanil, followed by an infusion of 
0.25 μg/kg/min, was as effective as a higher (double) dose at 
attenuating pressor responses to laryngoscopy and tracheal 
intubation. Furthermore, a low-dose remifentanil regimen, 
identical to that used in our study was shown to be as effective 
as an equipotent dose of alfentanil to attenuate hemodynamic 
responses to tracheal intubation in hypertensive patients 
[12]. In these previous investigations done in westerners, the 
low-dose regimen of remifentanil produced a similar pattern 
of hemodynamic responses to tracheal intubation: HR and 
arterial pressures decreased after induction of anesthesia, 
then increased with tracheal intubation without exceeding 
baseline values [11,12,15-18]. In the investigations done in 
Koreans, however, greater sensitivity to remifentanil, given 
either by bolus or infusion, was demonstrated with no further 
increases in hemodynamic responses even after intubation 
[13,14]. Therefore, we chose this lowest effective dosage 
of remifentanil to evaluate the efficacy of a lower dose of 
remifentanil to treat hemodynamic responses to tracheal 
intubation. Hemodynamic responses in our study showed a 
similar pattern to that reported in the previous investigations, 
except for elevations in HR and arterial pressures over baseline 
values immediately after intubation. These relatively larger 
increments in hemodynamic parameters can be attributed to 
vagolytic pretreatment for prevention of bradycardia and/or 
hypotension with remifentanil [11,16], along with the fact that 
we did not give volatile anesthetics during mask ventilation 
before tracheal intubation. Although hemodynamic variables 
were elevated over the baseline values in all groups, patients 
in Group KH showed no statistically significant increases, 
which was probably attributed to a certain stabilizing effect of 
ongoing antihypertensive therapy. Elevated HR and arterial 
Fig. 1. Line-scatter plots (A and B) depict the alterations in heart rate (HR) and mean arterial pressure (MAP), respectively, over nine time points 
during induction of anesthesia and tracheal intubation, showing intra-group comparisons in Group N (●), Group UH (○), and Group KH (▼). 
Values are mean ± SD. Group N: normotensive, Group UH: untreated hypertensive, Group KH: known hypertension. *P < 0.01, compared to 
baseline, †P < 0.001, compared to baseline, ‡P < 0.05, compared to baseline.
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pressures quickly decreased to below the baseline values; even 
though HR in Group N remained higher than baseline until 
5 min after intubation without clinical relevance (HR values 
were < 90/min). It is encouraging that in our study, a low-dose, 
single regimen of remifentanil produced similar hemodynamic 
responses to induction and tracheal intubation in patients with 
diverse cardiovascular conditions. Although MAP changes 
over time in the untreated hypertensive patients were shown to 
statistically different from those in normotensive patients with 
relatively larger amplitude of pressure swing, this exaggerated 
response to induction and intubation was so brief (< 1-2 min) 
that clinically it only necessitates an adequate rescue regimen 
for hemodynamic stabilization in those patients. Adverse events, 
such as hypotension and/or bradycardia, were observed in 
fewer cases compared to previous investigations (about 1% vs. 
10%, respectively) [11,15]. In our study, rescue medications 
were mostly used to treat hypertension after tracheal intubation, 
more frequently in Group UH. Inadequate protection against 
hyperdynamic responses to intubation might be a concern. 
These augmented hemodynamic responses, however, were 
short-lived and well-controlled with predetermined rescue 
medications. Furthermore, twice the number of hypertension 
and/or tachycardia incidents during induction and intubation 
were reported in the multicenter study by Hogue et al. [18] 
com pared with our study (10% vs. 21% for hypertension, 
respectively), in which twice the remifentanil dosage used in 
our study was employed as a “small dose”. To summarize, a low-
dose regimen of remifentanil in this study can stabilize hemo-
dynamics before intubation and limit hemodynamic responses 
to tracheal intubation without excessive cardio vascular de-
pression.
Our study has certain limitations. First, disparities between 
patients in terms of their characteristics and baseline hemo-
dynamic profiles may nullify the assumption of randomization. 
However, this disparity is likely to be a reflection of epidemio-
logic properties of hypertension; for example, the prevalence of 
hypertension increases with advanced age, and women have 
been shown to have better awareness, treatment and control 
of hypertension [19]. To achieve hemodynamic stability during 
induction of anesthesia, target-controlled infusion would be a 
better choice than weight-adjusted bolus administration [20]. 
When designing the study, however, our primary goal was to 
emulate as closely as possible the ordinary routine practice 
of anesthesia. A variety of antihypertensive medications were 
used in Group KH, making it difficult to evaluate the effect of 
individual class of those agents, due to low statistical power. 
Although pressor responses to intubation are reportedly 
not affected by antihypertensive agents [21], this must be 
evaluated in the future in hypertensive patients who are 
administered novel antihypertensive agents. As hemodynamic 
and neuroendocrine responses to tracheal intubation have 
been shown to be limited for 5 min [22], we designed our study 
accordingly. However, it is important to evaluate whether the 
hemodynamic responses measured for “several minutes” 
after intubation could affect perioperative outcomes [23]. As 
mentioned above, greater sensitivity to remifentanil in Koreans 
was demonstrated in the investigations in Koreans [13,14] and 
could be extrapolated from the similarity of ED50 of remifentanil 
for awake fiberoptic intubation reported in patients of similar 
East Asian descent [24]. However, further randomized study in 
large numbers of patients is required for clarification.
In conclusion, a low-dose regimen of remifentanil in our 
study limited pressor responses to intubation effectively, and 
produced similar hemodynamic responses among various 
groups of patients without excessive cardiovascular depression. 
However, the relatively larger alterations in hemodynamic 
responses observed in our study indicate the necessity 
of developing supplementary regimens to control those 
exaggerated responses, especially in the untreated hypertensive 
patients. Thus, we suggest that low-dose regimen of remifentanil 
in our study could be commonly used to modify hemodynamic 
responses to tracheal intubation in patients with various 
hemodynamic characteristics if adequate rescue therapy is 
readily prepared. 
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